Skip to content

Released Aug 13, 2024, after the close

10-Q filed Aug 13, 2024, 44 days after period end · 0001390478-24-000015

Q2 2024 · 10-Q
Revenue—
Net Income-$7.47MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.13N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$7,621,000N/M
Operating Cash Flowderived-$9,682,000N/M

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue—$0.00$0.00$1.90M
Net Income-$7.47M-$8.84M-$8.41M-$4.61M
EPS Diluted-$0.13-$0.31-$0.41-$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR